.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: RE39198

« Back to Dashboard

Claims for Patent: RE39198

Title:Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analgesics
Abstract:Heteroarylpiperidines, pyrrolidines, and piperazines are useful as antipsychotic and analgesic agents. The compounds are especially useful for treating psychoses by administering to a mammal a psychoses-treating effective amounts of one of the compounds. The compounds are also useful as analgesics by administering a pain-relieving effective amount of one of the compounds to a mammal.
Inventor(s): Strupczewski; Joseph T. (Flemington, NJ), Helsley; Grover C. (Rosemont, NJ), Chiang; Yulin (Convent Station, NJ), Bordeau; Kenneth J. (Kintnersville, PA), Glamkowski; Edward J. (Warren, NJ)
Assignee: Aventis Pharmaceuticals Inc. (Bridgewater, NJ)
Application Number:09/712,129
Patent Claims: 1. A compound of the formula: ##STR00166## wherein X is --O-- or --S--; p is 1 or 2; Y is hydrogen, lower alkyl, hydroxy, chlorine, fluorine, bromine, iodine, lower alkoxy, trifluoromethyl, nitro, or amino, when p is 1; Y is lower alkoxy.[., hydroxy and halogen.]. when p is 2 and X is --O--; .[.(R.sub.1) is R.sub.20, R.sub.21, or R.sub.22, wherein: R.sub.20 is --(CH.sub.2).sub.n-- where.]. n is 2, 3, 4 or 5; .[.R.sub.21 is --CH.sub.2--CH.dbd.CH--CH.sub.2--, --CH.sub.2--C.ident.C--CH.sub.2--, --CH.sub.2--CH.dbd.CH--CH.sub.2--CH.sub.2, --CH.sub.2--CH.sub.2--CH.dbd.CH--CH.sub.2--, --CH.sub.2--C.ident.C--CH.sub.2--CH.sub.2--, or --CH.sub.2--CH.sub.2--C.ident.C--CH.sub.2--, the --CH.dbd.CH-- bond being cis or trans; R.sub.22 is R.sub.20 or R.sub.21 in which one or more carbon atoms of R.sub.20 or R.sub.21 are substituted by at least one C.sub.1-C.sub.6 linear alkyl group, pheny group or ##STR00167## where Z.sub.1 is lower alkyl, --OH, lower alkoxy, --CF.sub.3, --NO.sub.2, --NH.sub.2 or halogen;.]. R is hydrogen, lower alkyl, lower alkoxy, hydroxyl, carboxyl, chlorine, fluorine, bromine, iodine, amino, lower mono or dialkylamino, nitro, lower alkyl thio, trifluoromethoxy, cyano, acylamino, trifluoromethyl, trifluoroacetyl, aminocarbonyl, .[.monoalkylaminocarbonyl, dialkylaminocarbonyl, formyl,.]. --C(.dbd.O)-alkyl, --C(.dbd.O)--O-alkyl, --C(.dbd.O)-aryl, --C(.dbd.O)-heteroaryl, .[.--CH(OR.sup.7)-alkyl, --C(.dbd.W)-alkyl, --C(.dbd.W)-aryl, and --C(.dbd.W)-heteroaryl;.]. .Iadd.or --CH(OR.sub.7)-alkyl; wherein .Iaddend.alkyl is lower alkyl; aryl is phenyl or ##STR00168## where.Iadd.in .Iaddend.R.sub.5 is hydrogen, lower alkyl, lower alkoxy, hydroxy, chlorine, fluorine, bromine, iodine, lower monoalkylamino, .[.lower dialkylamino,.]. nitro, cyano, trifluoromethyl, .Iadd.or .Iaddend.trifluoromethoxy; heteroaryl is ##STR00169## .Iadd.wherein .Iaddend.Q.sub.3 is --O--, --S--, --NH--, .Iadd.or .Iaddend.--CH.dbd.N--; .[.W is CH.sub.2 or CHR.sub.8 or N--R.sub.9;.]. R.sub.7 is hydrogen, lower alkyl, or acyl; .[.R.sub.8 is lower alkyl; R.sub.9 is hydroxy, lower alkoxy, or --NHR.sub.10; and R.sub.10 is hydrogen, lower alkyl, C.sub.1-C.sub.3 acyl, aryl, --C(.dbd.)-aryl or --C(.dbd.O)-heteroaryl, where aryl and heteroaryl are as defined above;.]. and m is 1, 2, or 3; .[.all geometric, optical and stereoisomers thereof,.]. or a pharmaceutically acceptable acid addition salt thereof.

2. A compound as claimed in claim 1, which is 1-[4-[3-[4-(1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl- ]ethanone or a pharmaceutically acceptable acid addition salt thereof.

3. A compound as claimed in claim 1, which is 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-propoxy]-3-met- hoxyphenyl]ethanone or a pharmaceutically acceptable acid addition salt thereof.

4. A compound as claimed in claim 1, which is 1-[4-[4-[4-(1,2-benzisoxazol-3-yl)-1-piperidinyl]butoxy]-3-methoxyphenyl]- ethanone or a pharmaceutically acceptable acid addition salt thereof.

5. A compound as claimed in claim 1, which is 1-[4-[4-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]butoxy]-3-metho- xyphenyl]ethanone or a pharmaceutically acceptable acid addition salt thereof.

6. A compound as claimed in claim 1, which is 1-[4-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperidinyl]ethoxy]-3-methoxyphenyl]- ethanone or a pharmaceutically acceptable acid addition salt thereof.

7. A compound as claimed in claim 1, which is 1-[4-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethoxy-3-methox- yphenyl]ethanone or a pharmaceutically acceptable acid addition salt thereof.

8. A compound as claimed in claim 1, which is 1-[4-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphen- yl]ethanone or a pharmaceutically acceptable acid addition salt thereof.

9. A compound as claimed in claim 1, which is 4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy- -.alpha.-methylbenzenemethanol or a pharmaceutically acceptable acid addition salt thereof.

10. A compound as claimed in claim 1, which is 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-propoxy]-3-hyd- roxyphenyl]ethanone or a pharmaceutically acceptable acid addition salt thereof.

11. A compound as claimed in claim 1, which is 1-[4-[3-[4-(6-chloro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-propoxy]-3-met- hoxyphenyl]ethanone or a pharmaceutically acceptable acid addition salt thereof.

12. A compound as claimed as claim 1, which is 1-[4-[4-[4-(6-chloro-1,2-benzisoxazol-3-yl)-1-piperindyl]-butoxy]-3-metho- xyphenyl]ethanone or a pharmaceutically acceptable acid addition salt thereof.

13. A compound as claimed in claim 1, which is 1-[4-[3-[4-(5-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-propoxy]-3-met- hoxyphenyl]ethanone or a pharmaceutically acceptable acid addition salt thereof.

14. A compound as claimed in claim 1, which is 6-fluoro-3-[1-[1-[3-(2-methoxyphenoxy)propyl]-4-piperidinyl]-1,2-benzisox- azole or a pharmaceutically acceptable acid salt thereof.

15. A compound as claimed in claim 1, which is 1-[3-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-propoxy]-4-met- hoxyphenyl]phenylmethanone or a pharmaceutically acceptable acid addition salt thereof.

16. A compound as claimed in claim 1, which is 1-[4-[2-[4-(6-chloro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethoxy]-3-metho- xyphenyl]ethanone or a pharmaceutically acceptable acid addition salt thereof.

17. A compound as claimed in claim 1, which is 1-[3-[3-[4-(6-fluoro-1,2-benzisoxzol-3-yl)-1-piperidinyl]-propoxy]phenyl]- ethanone or a pharmaceutically acceptable acid addition salt thereof.

18. A compound as claimed in claim 1, which is 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3yl)-1-piperidinyl]-propoxyl]-2-met- hylphenyl]ethanone or a pharmaceutically acceptable acid addition salt thereof.

19. A compound as claimed in claim 1, which is 1-[2-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-propoxy]-5-met- hylphenyl]ethanone or a pharmaceutically acceptable acid addition salt thereof.

20. A compound as claimed in claim 1, which is N-[3-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-propoxy]-4-met- hoxyphenyl]acetamide or a pharmaceutically acceptable acid addition salt thereof.

21. A compound as claimed in claim 1, which is 1-(4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-propoxy]-3-met- hylphenyl]ethanone or a pharmaceutically acceptable acid addition salt thereof.

22. A compound as claimed in claim 1, which is 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-propoxy]phenyl- ]ethanone or a pharmaceutically acceptable acid addition salt thereof.

23. A compound as claimed in claim 1, which is 4-[3-[4-(6-fluoro-1,2-1,2-benzisoxazol-3-yl)-1-piperidinyl]-propoxy]-3-me- thoxybenzonitrile or a pharmaceutically acceptable acid addition salt thereof.

24. A compound as claimed in claim 1, which is 1-[3,5-dibromo-4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]pro- poxy]phenyl]ethanone or a pharmaceutically acceptable acid addition salt thereof.

25. A compound as claimed in claim 1, which is 6-fluoro-3-[1-(3-phenoxypropyl)-4-piperidinyl]-1,2-benzisoxazole or a pharmaceutically acceptable acid addition salt thereof.

26. A compound as claimed in claim 1, which is .[.1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl]-1-piperidinyl]-propoxy]-3-- methylmercaptophenyl]ethanone.]. .Iadd.1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-- 3-methylmercaptophenyl]ethanone .Iaddend.or a pharmaceutically acceptable acid addition salt thereof.

27. A compound as claimed in claim 1, which is 1-[4-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperidinyl]butoxy]-3-methoxypheny- l]ethanone or a pharmaceutically acceptable acid addition salt thereof.

28. A compound as claimed in claim 1, which is 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-propoxy]-3-met- hoxyphenyl]phenylmethanone or a pharmaceutically acceptable acid addition salt thereof.

29. A compound as claimed in claim 1, which is 3-[1-[3-[4-ethoxyethyl)-2-methoxyphenoxy]propyl]-4-piperidinyl]-6-fluoro-- 1,2-benzisoxazole or a pharmaceutically acceptable acid addition salt thereof.

30. A compound as claimed in claim 1, which is 3-[1-[3-[4-(1-acetoxyethyl)-2-methoxyphenoxy]propyl]-4-piperidinyl]-6-flu- oro-1,2-benzisoxazole or a pharmaceutically acceptable acid addition salt thereof.

31. A compound as claimed in claim 1, which is 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-propoxy]-3-met- hoxyphenyl]pentanone or a pharmaceutically acceptable acid addition salt thereof.

32. A compound as claimed in claim 1, which is 2-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-propoxy]-N-methyl- benzeneamine or a pharmaceutically acceptable acid addition salt thereof.

33. A compound as claimed in claim 1, which is 3-[1-[3-(4-bromo-2-methoxyphenoxy)propyl]-4-piperidinyl]-6-fluoro-1,2-ben- zisoxazole or a pharmaceutically acceptable acid addition salt thereof.

34. A compound as claimed in claim 1, which is 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-propoxy]-3-met- hoxyphenyl]propanone or a pharmaceutically acceptable acid addition salt thereof.

35. A compound as claimed in claim 1, which is 4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-propoxy]-3-methox- ybenzamide or a pharmaceutically acceptable acid addition salt thereof.

36. A compound as claimed in claim 1, which is 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-propoxy]-3-(me- thylamino)phenyl]ethanone or a pharmaceutically acceptable acid addition salt thereof.

37. A compound as claimed in claim 1, which is 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-propoxy]-3-eth- oxyphenyl]ethanone or a pharmaceutically acceptable acid addition salt thereof.

38. A compound as claimed in claim 1, which is N-[2-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-propoxy]phenyl- ]acetamide, or a pharmaceutically acceptable acid addition salt thereof.

39. A compound as claimed in claim 1, which is 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-propoxy]-3-dim- ethylaminophenyl]ethanone, or a pharmaceutically acceptable acid addition salt thereof.

40. A compound as claimed in claim 1, which is 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-propoxy]-2-met- hoxyphenyl]ethanone, or a pharmaceutically acceptable acid addition salt thereof.

41. A compound as claimed in claim 1, which is 4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-propoxy]-3-hydrox- y-.alpha.-methylbenzene methanol, or a pharmaceutically acceptable acid addition salt thereof.

42. A compound as claimed in claim 1, which is 2-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-propoxy]aniline, or a pharmaceutically acceptable acid addition salt thereof.

43. A compound as claimed in claim 1, which is N-[5-acetyl-2-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propox- y]phenyl]acetamide, or a pharmaceutically acceptable acid addition salt thereof.

44. A compound as claimed in claim 1, which is 3-[1-[3-(4-ethyl-2-methoxyphenoxy)propyl]-4-piperidinyl]-6-fluoro-1,2-ben- zisoxazole, or a pharmaceutically acceptable acid addition salt thereof.

45. A compound as claimed in claim 1, which is 1-[3,5-dimethoxy-4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]p- ropoxy]phenyl]ethanone, or a pharmaceutically acceptable acid addition salt thereof.

46. A compound as claimed in claim 1, which is N-[3-[3-[4-(6-fluoro-1,2-benzisoxaxol-3-yl)-1-piperidinyl]-propoxy]phenyl- ]acetamide, or a pharmaceutically acceptable acid addition salt thereof.

47. A compound as claimed in claim 1, which is 3-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-propoxy]aniline, or a pharmaceutically acceptable acid addition salt thereof.

48. A compound as claimed in claim 1, which is 3-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-propoxy]-4-methox- yaniline, or a pharmaceutically acceptable acid addition salt thereof.

49. A compound as claimed in claim 1, which is 1-[4-[3-[4-(6-fluoro-1,2-benzisothiazol-3-yl)-1-piperidinyl]-propoxy]-3-m- ethylaminophenyl]ethanone, or a pharmaceutically acceptable acid addition salt thereof.

50. A compound as claimed in claim 1, which is N-[3-[3-[4-(6-fluoro-1,2-benzisothiazol-3-yl)-1-piperidinyl]-propoxy]-4-m- ethoxyphenyl]acetamide, or a pharmaceutically acceptable acid addition salt thereof.

51. A compound as claimed in claim 1, which is 1-[4-[3-[4-(6-fluoro-1,2-benzisothiazol-3-yl)-1-piperidinyl]-propoxy]-3-m- ethoxyphenyl]ethanone, or a pharmaceutically acceptable acid addition salt thereof.

52. A compound as claimed in claim .[.1.]. .Iadd.132.Iaddend., which is N,N-dimethyl-4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propo- xy]-3-methoxybenzamide, or a pharmaceutically acceptable acid addition salt thereof.

53. A compound as claimed in claim .[.1.]. .Iadd.132.Iaddend., which is 1-[4-[3-[4(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-propoxy]-3-(met- hylamino)phenyl]ethanone oxime, or a pharmaceutically acceptable acid addition salt thereof.

54. A compound as claimed in claim .[.1.]. .Iadd.132.Iaddend., which is 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-propoxy]methox- yphenyl]ethanone oxime O-methyl ether, or a pharmaceutically acceptable acid addition salt thereof.

55. A compound as claimed in claim .[.1.]. .Iadd.132.Iaddend., which is 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-propoxy]-3-met- hoxyphenyl]ethanone hydrazone, or a pharmaceutically acceptable acid addition salt thereof.

56. A compound as claimed in claim .[.1.]. .Iadd.132.Iaddend., which is 6-fluoro-3-[1-[3-[2-methoxy-4-(1-methylethenyl)phenoxy]propyl]-4-piperidi- nyl]-1,2-benzisoxazole, or a pharmaceutically acceptable acid addition salt thereof.

57. A compound as claimed in claim .[.1.]. .Iadd.87.Iaddend., which is (Z)-1-[4-[[4-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2butenyl]- oxy]-3-methoxyphenyl]ethanone, or a pharmaceutically acceptable acid addition salt thereof.

58. A compound as claimed in claim .[.1.]. .Iadd.87.Iaddend., which is (E)-1-[3-[4-[[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-butenyl- ]oxy]-4-hydroxyphenyl]ethanone, or a pharmaceutically acceptable acid addition salt thereof.

59. A compound .[.as claimed in claim 1.]. , which is (E)-1-[3-[4-[[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2butenyl]- oxy]-4-benzyloxyphenyl]ethanone, or a pharmaceutically acceptable acid addition salt thereof.

60. A compound as claimed in claim 1, which is 1-[4-[3-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-propoxy]-3-bro- mophenyl]ethanone or a pharmaceutically acceptable acid addition salt thereof.

61. A compound as claimed in claim 1, which is 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-propoxy]-3-met- hoxyphenyl]-2,2,2-trifluoroethanone, or a pharmaceutically acceptable acid addition salt thereof.

62. A compound as claimed in claim 1, which is 3-[1-[3-[4-(1-methoxyethyl)-2-hydroxyphenoxyl]propyl]-4-piperidinyl]-6-fl- uoro-1,2-benzisoxazole, or a pharmaceutically acceptable acid addition salt thereof.

63. A compound as claimed in claim 1, which is 1-[4-[3-[4-(6-fluoro-1,2-benzisothazol-3-yl)-1-piperidinyl]-propoxy]-3-hy- droxyphenyl]ethanone, or a pharmaceutically acceptable acid addition salt thereof.

64. A compound as claimed in claim 1, which is 4-[3-[4-(6-fluoro-1,2-benzisothiazol-3-yl)-1-piperidinyl]-propoxy]-3-meth- oxy-alpha-methylbenzenemethanol, or a pharmaceutically acceptable acid addition salt thereof.

65. A compound as claimed in claim .[.1, which is 1-(R)-(-)-[4-[3-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-methyl-- 1-propoxy]-3-methoxyphenyl]ethanone, or.]. .Iadd.104, which is 1-(R)-(-)-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-meth- yl-1-propoxy]-3-methoxyphenyl]ethanone, or .Iaddend.a pharmaceutically acceptable acid addition salt thereof.

66. A compound as claimed in claim .[.1.]. .Iadd.104.Iaddend., which is 1-(S)-(+)-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-meth- yl-1-propoxy]-3-methoxyphenyl]ethanone, or a pharmaceutically acceptable acid addition salt thereof.

67. The compound of claim 1, wherein the pharmaceutically acceptable addition salt is selected from the group consisting of salts of mineral acids, salts of monobasic carboxylic acids, slats of dibasic carboxylic acids, and salts of tribasic carboxylic acids.

68. The compound of claim 67, wherein said pharmaceutically acceptable addition salts are selected from the group consisting of salts of hydrochloric acid, sulfuric acid, nitric acid, acetic acid, propionic acid, maleic acid, fumaric acid, carboxysuccinic acid, and citric acid.

69. The compound of claim 1, wherein Y is in the 5 position.

70. The compound of claim 1, wherein Y is in the 6 position.

71. The compound of claim 1, wherein Y is selected from the group consisting of hydrogen, chlorine, bromine and fluorine.

72. The compound of claim 71, wherein Y is fluorine.

73. The compound of claim 72, wherein Y is in the 6 position.

74. The compound of claim 1, wherein p is 2, X is --O--, and Y is .[.selected from the group consisting of.]. lower alkoxy.[., hydroxy and halogen groups.]. .

75. The compound of claim 74, wherein Y is a methoxy group.

.[.76. The compound of claim 1, wherein R.sub.1 is --CH.sub.2--CH.dbd.CH--CH.sub.2--..].

77. The compound of claim 1, wherein R is selected from the group consisting of hydrogen, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3alkoxy, hydroxyl, --COCF.sub.3, C.sub.1-C.sub.6alkanoyl, Cl, F, Br, I, C.sub.1-C.sub.3 alkylamino, .[.--NO.sub.3,.]. .Iadd.--NO.sub.2.Iaddend., --CF.sub.3, --OCF.sub.3, and --C(.dbd.O)-lower alkyl.

78. A compound of the formula: ##STR00170## wherein p is 1 or 2; Y is hydrogen, Cl, Br, or F, when p is 1; Y is lower alkoxy, .[.hydroxy, or halogen.]. when p is 2; n is 2, 3, or 4; R is hydrogen, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 alkoxy, hydroxyl, .[.alkanoyl,.]. Cl, F, Br, I, amino, C.sub.1-C.sub.3 mono or dialkyl amino, acylamino, --NO.sub.2, --OCF.sub.3, --CF.sub.3, alkyl-C(.dbd.O)--, CF.sub.3--C(.dbd.O)--, or --CH(OR.sub.7)-alkyl; alkyl is lower alkyl R.sub.7 is hydrogen, lower alkyl-C(.dbd.O)--, or CF.sub.3--C(.dbd.O)--; and m is 1, 2, or 3; R is hydrogen, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 alkoxy, hydroxyl, .[.alkanoyl,.]. Cl, F, Br, I, amino, C.sub.1-C.sub.3 mono or dialkyl amino, acylamino, --NO.sub.2, --OCF.sub.3, --CF.sub.3, alkyl-C(.dbd.O)--, CF.sub.3--C(.dbd.O)--, or --CH(OR.sub.7)-alkyl; alkyl is lower alkyl; R.sub.7 is hydrogen, lower alkyl, lower alkyl-C(.dbd.O)--, or CF.sub.3--C(.dbd.O)--; and m is 1, 2, or 3; all geometric, optical and stereoisomers thereof or a pharmaceutically acceptable acid addition salt thereof.

79. A compound of the formula: ##STR00171## wherein p is 1 or 2; Y is hydrogen, Cl, Br, or F, when p is 1; Y is lower alkoxy, .[.hydroxy, or halogen.]. when p is 2; n is 2, 3, or 4; R is hydrogen, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 alkoxy, hydroxyl, acyl, alkanoyl, Cl, F, Br, I, amino, C.sub.1-C.sub.3 mono or dialkyl amino, acylamino, --NO.sub.2, --OCF.sub.3, --CF.sub.3, alkyl-C(.dbd.O)--, CF.sub.3--C(.dbd.O)--, or --CH(OR.sub.7)-alkyl; alkyl is lower alkyl; R.sub.7 is hydrogen lower alkyl, .[.or.]. lower alkyl-C(.dbd.O)--, .Iadd.or .Iaddend.CF.sub.3--C(.dbd.O)--; and m is 1, 2, or 3; all geometric, optical and stereoisomers thereof or a pharmaceutically acceptable acid addition salt thereof.

80. A compound .[.of the formula: ##STR00172## wherein X is --O-- or --S--; p is 1 or 2; Y is hydrogen, lower alkyl, hydroxy, chlorine, fluorine, bromine, iodine, lower alkoxy, trifluoromethyl, nitro, or amino, when p is 1; Y is lower alkoxy, hydroxy and halogen when p is 2 and X is --O--, (R.sub.1) is R.sub.20, R.sub.21, or R.sub.22, wherein: R.sub.20 R.sub.21 is --CH.sub.2 --CH.dbd.CH--CH.sub.2--, --CH.sub.2--C.ident.C--CH.sub.2--, --CH.sub.2--CH.dbd.CH--CH.sub.2--CH.sub.2 --, --CH.sub.2--CH.sub.2--CH.dbd.CH--CH.sub.2--, --CH.sub.2--CH.ident.C--CH.sub.2--CH.sub.2--, or --CH.sub.2--CH.sub.2--C.ident.C--CH.sub.2--, the --CH.dbd.CH-- bond being cis or trans; R.sub.22 is R.sub.20 is R.sub.21 in which one or more carbon atoms of R.sub.20 or R.sub.21 are substituted by at least one C.sub.1-C.sub.6 linear alkyl group, phenyl group or ##STR00173## wherein Z.sub.1 is lower alkyl, --OH, lower alkoxy, --CF.sub.3, --NO.sub.2, --NH.sub.2 or halogen; and R and m are as defined hereinafter; m is 1, 2, or 3; and when m is 1, 2, or 3, R is hydrogen, lower alkyl, lower alkoxy, hydroxyl, carboxyl, chlorine, fluorine, bromine, iodine, amino, lower mono or dialkylamino, nitro, lower alkyl thio, trifluoromethoxy, cyano, acylamino, trifluoromethyl, trifluoroacetyl, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, formyl, --C(.dbd.O)-alkyl, --C(.dbd.O)--O-alkyl, --C(.dbd.O)-aryl, --C(.dbd.O)-heteroaryl, --CH(OR.sup.7)-alkyl, --C(.dbd.W)-alkyl, --C(.dbd.W)-aryl, and --C(.dbd.W)-heteroaryl; alkyl is lower alkyl; aryl is phenyl or ##STR00174## where R.sub.5 is hydrogen, lower alkyl, lower alkoxy, hydroxy, chlorine, fluorine, bromine, iodine, lower monoalkylamino, lower dialkylamino, nitro, cyano, trifluoromethyl, trifluoromethoxy; heteroaryl is ##STR00175## Q.sub.3 is --O--, --S--, --NH--, --CH.dbd.N--; W is CH.sub.2 or CHR.sub.8 or N--R.sub.9; R.sub.7 is hydrogen, lower alkyl, or acyl; R.sub.8 is lower alkyl; R.sub.9 is hydroxy, lower alkoxy, or --NHR.sub.10; and R.sub.10 is hydrogen, lower alkyl, C.sub.1-C.sub.3 acyl, aryl, --C(.dbd.O)-aryl or --C(.dbd.O)-heteroaryl, where aryl and heteroaryl are as defined above; and.]. .Iadd.as claimed in claim 1 with the proviso that .Iaddend.when m is 3, R is not --C(.dbd.O)-heteroaryl or --C(.dbd.W)-heteroaryl; .[.all geometric, optical and stereoisomers thereof,.]. or .Iadd.a .Iaddend.pharmaceutically acceptable acid addition salt thereof.

81. A compound as claimed in claim .[.1.]. .Iadd.87.Iaddend., which is (E)-1-[4-[[4-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-butenyl- ]oxy]-3-methoxyphenyl]ethanone, or a pharmaceutically acceptable acid addition salt thereof.

82. A pharmaceutical composition, which comprises .Iadd.a .Iaddend.compound as claimed in any one of claims .[.1-81.]. .Iadd.1-75 and 77-81.Iaddend., and a pharmaceutically acceptable carrier therefor.

83. An antipsychotic composition which comprises a compound as claimed in any one of claims .[.1-81.]. .Iadd.1-75 and 77-81.Iaddend., in an amount sufficient to produce an antipsychotic effect, and a pharmaceutically acceptable carrier therefor.

84. A method of treating psychoses, which comprises administering to a mammal a psychoses-treating effective amount of a compound as claimed in any one of claims .[.1-81.]. .Iadd.1-75 and 77-81.Iaddend..

85. An analgesic composition which comprises a compound as claimed in any one of claims .[.1-81.]. .Iadd.1-75 and 77-81.Iaddend., in an amount sufficient to produce a pain-relieving effect, and a pharmaceutically acceptable carrier therefor.

86. A method of alleviating pain, which comprises administering to a mammal a pain-relieving effective amount of a compound as claimed in any one of claims .[.1-81.]. .Iadd.1-75 and 77-81.Iaddend..

.Iadd.87. A compound of the formula ##STR00176## wherein X is --O-- or --S--; p is 1 or 2; Y is hydrogen, lower alkyl, hydroxy, chlorine, fluorine, bromine, iodine, lower alkoxy, trifluoromethyl, nitro, or amino, when p is 1; Y is lower alkoxy, hydroxy and halogen, when p is 2 and X is --O--; (R.sub.1) is --CH.sub.2--CH.dbd.CH--CH.sub.2--, --CH.sub.2--C.ident.C--CH.sub.2--, --CH.sub.2--CH.dbd.CH--CH.sub.2--CH.sub.2--, --CH.sub.2--CH.sub.2 --CH.dbd.CH--CH.sub.2--, --CH.sub.2--C.ident.C--CH.sub.2 --CH.sub.2--, or --CH.sub.2--CH.sub.2--C.ident.C--CH.sub.2--, the --CH.dbd.CH-- bond being cis or trans; R is hydrogen, lower alkyl, lower alkoxy, hydroxyl, carboxyl, chlorine, fluorine, bromine, iodine, amino, lower mono or dialkylamino, nitro, lower alkyl thio, trifluoromethoxy, cyano, acylamino, trifluoromethyl, trifluoroacetyl, aminocarbonyl, dialkylaminocarbonyl, formyl, --C(.dbd.O)-alkyl, --C(.dbd.O)--O-alkyl, --C(.dbd.O)-aryl, --C(.dbd.O)-heteroaryl, --CH(OR.sub.7)-alkyl, --C(.dbd.W)-alkyl, --C(.dbd.W)-aryl, or --C(.dbd.W)-heteroaryl; wherein alkyl is lower alkyl; aryl is phenyl or ##STR00177## wherein R.sub.3 is hydrogen, lower alkyl, lower alkoxy, hydroxy, chlorine, fluorine, bromine, iodine, lower monoalkylamino, lower dialkylamino, nitro, cyano, trifluoromethyl, or trifluoromethoxy; heteroaryl is ##STR00178## wherein Q.sub.3 is --O--, --S--, --NH--, or --CH.dbd.N--; W is CH.sub.2 or CHR.sub.8 or N--R.sub.9; R.sub.7 is hydrogen, lower alkyl, or acyl; R.sub.8 is lower alkyl; R.sub.9 is hydroxy, lower alkoxy, or --NHR.sub.10; and R.sub.10 is hydrogen, lower alkyl, C.sub.1-C.sub.3 acyl aryl, --C(.dbd.O)-aryl, or --C(.dbd.O)-heteroaryl, wherein aryl and heteroaryl are as defined above; and m is 1, 2, or 3; all geometric, optical and stereoisomers thereof, or a pharmaceutically acceptable acid addition salt thereof..Iaddend.

.Iadd.88. The compound of claim 87, wherein the pharmaceutically acceptable addition salt is selected from the group consisting of salts of minerals acids, salts of monobasic carboxylic acids, salts of dibasic carboxylic acids, and salts of tribasic carboxylic acids..Iaddend.

.Iadd.89. The compound of claim 88, wherein said pharmaceutically acceptable addition salts are selected from the group consisting of salts of hydrochloric acid, sulfuric acid, nitric acid acetic acid, propionic acid, maleic acid, fumaric acid, carboxysuccinic acid, and citric acid..Iaddend.

.Iadd.90. The compound of claim 87, wherein Y is in the 5 position..Iaddend.

.Iadd.91. The compound of claim 87, wherein Y is in the 6 position..Iaddend.

.Iadd.92. The compound of claim 87, wherein Y is selected from the group consisting of hydrogen, chlorine, bromine and fluorine..Iaddend.

.Iadd.93. The compound of claim 92, wherein Y is fluorine..Iaddend.

.Iadd.94. The compound of claim 93, wherein Y is in the 6 position..Iaddend.

.Iadd.95. The compound of claim 87, wherein p is 2, X is --O--, and Y is selected from the group consisting of lower alkoxy, hydroxy, and halogen groups..Iaddend.

.Iadd.96. The compound of claim 95, wherein Y is a methoxy group..Iaddend.

.Iadd.97. The compound of claim 87, wherein R.sub.7 is --CH.sub.2--CH.dbd.CH--CH.sub.2.Iaddend..

.Iadd.98. The compound of claim 87, wherein R is selected from the group consisting of hydrogen, C.sub.1--C.sub.3 alkyl, C.sub.1--C.sub.3 alkoxy, hydroxyl, --COCF.sub.2, C.sub.1-C.sub.6 alkanoyl, Cl, F, Br, I, C.sub.1-C.sub.3 alkylamino, --NO.sub.2, --CF.sub.3, --OCF.sub.2, and alkylamino, ##STR00179## .Iaddend.

.Iadd.99. A pharmaceutical composition, which comprises a compound as claimed in claim 87, and a pharmaceutically acceptable carrier therefor..Iaddend.

.Iadd.100. An antipsychotic composition which comprises a compond as claimed in claim 87, in an amount sufficient to produce an antipsychotic effect, and a pharmaceutically acceptable carrier therefor..Iaddend.

.Iadd.101. A method of treating psychoses, which comprises administering to a mammal a psychoses-treating effective amount of a compound as claimed in claim 87..Iaddend.

.Iadd.102. An analgesic composition which comprises a compound as claimed in claim 87, in an amount sufficient to produce a pain-relieving effect, and a pharmaceutically acceptable carrier therefor..Iaddend.

.Iadd.103. A method of alleviating pain, which comprises administering to a mammal a pain-relieving effective amount of a compound as claimed in claim 87..Iaddend.

.Iadd.104. A compound of the formula ##STR00180## wherein X is --O-- or --S--; p is 1 or 2; Y is hydrogen, lower alkyl, hydroxy, chlorine, fluorine, bromine, iodine, lower alkoxy, trifluoromethyl, nitro, or amino, when p is 1; Y is lower alkoxy, hydroxy, or halogen when p is 2 and X is --O--; (R.sub.1) is R.sub.20 or R.sub.21 in which one or more carbon atoms of R.sub.20 or R.sub.21 are substituted by at least one C.sub.1-C.sub.6 linear alkyl group, phenyl group or ##STR00181## wherein Z.sub.1 is lower alkyl, --OH, lower alkoxy, --CF.sub.3, --NO.sub.2, --NH.sub.2, or halogen..Iaddend.

.Iadd.105. The compound of claim 104, wherein the pharmaceutically acceptable addition salt is selected from the group consisting of salts of mineral acids, salts of monobasic carboxylic acids, salts of dibasic carboxylic acids, and salts of tribasic carboxylic acids..Iaddend.

.Iadd.106. The compound of claim 105, wherein said pharmaceutically acceptable addition salts are selected from the group consisting of salts of hydrochloric acid, sulfuric acid, nitric acid, acetic acid, propionic acid, maleic acid, fumaric acid, carboxysuccinic acid, and citric acid..Iaddend.

.Iadd.107. The compound of claim 104, wherein Y is in the 5 position..Iaddend.

.Iadd.108. The compound of claim 104, wherein Y is in the 6 position..Iaddend.

.Iadd.109. The compound of claim 104, wherein Y is selected from the group consisting of hydrogen, chlorine, bromine and fluorine..Iaddend.

.Iadd.110. The compound of claim 109, wherein Y is fluorine..Iaddend.

.Iadd.111. The compound of claim 110, wherein Y is in the 6 position..Iaddend.

.Iadd.112. The compound of claim 104, wherein p is 2, X is --O--, and Y is selected from the group consisting of lower alkoxy, hydroxy and halogen groups..Iaddend.

.Iadd.113. The compound of claim 112, wherein Y is a methoxy group..Iaddend.

.Iadd.114. The compound of claim 104, wherein R is selected from the group consisting of hydrogen, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 alkoxy, hydroxyl, --COCF.sub.3, C.sub.1-C.sub.6 alkanoyl, Cl, F, Br, I, C.sub.1-C.sub.3 alkylamino, ##STR00182## .Iaddend.

.Iadd.115. A pharmaceutical composition, which comprises a compound as claimed in claim 104, and pharmaceutically acceptable carrier therefor..Iaddend.

.Iadd.116. A antipsychotic composition which comprises a compound as claimed in claim 104, in an amount sufficient to produce an antipsychotic effect, and a pharmaceutically acceptable carrier therefor..Iaddend.

.Iadd.117. A method of treating psychoses, which comprises administering to a mammal a psychoses-treating effective amount of a compound as claimed in claim 104..Iaddend.

.Iadd.118. An analgesic composition which comprises a compound as claimed in claim 104, in an amount sufficient to produce a pain-relieving effect, and a pharmaceutically acceptable carrier therefor..Iaddend.

.Iadd.119. A method of alleviating pain, which comprises administering to a mammal a pain-relieving effective amount of a compound as claimed in claim 104..Iaddend.

.Iadd.120. A compound as claimed in claim 87, with the proviso that when m is 3, R is not --C(.dbd.O)-aryl, or --C(.dbd.O)-heteroaryl, all geometric, optical and stereoisomers thereof, or a pharmaceutically acceptable acid addition salt thereof..Iaddend.

.Iadd.121. A pharmaceutically composition, which comprises a compound as claimed in claim 120, and a pharmaceutically acceptable carrier therefor..Iaddend.

.Iadd.122. An antipsychotic composition which comprises a compound as claimed in claim 120, in an amount sufficient to produce an antipsychotic effect, and a pharmaceutically acceptable carrier therefor..Iaddend.

.Iadd.123. A method of treating psychoses, which comprises administering to a mammal a psychoses-treating effective amount of a compound as claimed in claim 120..Iaddend.

.Iadd.124. An analgesic composition which comprises a compound as claimed in claim 120, in an amount sufficient to produce a pain-relieving effect, and a pharmaceutically acceptable carrier therefor..Iaddend.

.Iadd.125. A method of alleviating pain, which comprises administering to a mammal a pain-relieving effective amount of a compound as claimed in claim 120..Iaddend.

.Iadd.126. A compound as claimed in claim 104, with the proviso that when m is 3, R is not --C(.dbd.O)-aryl, or --C(.dbd.O)-heteroaryl, all geometric, optical and stereoisomers thereof, or a pharmaceutically acceptable acid addition salt thereof..Iaddend.

.Iadd.127. A pharmaceutical composition, which comprises a compound as claimed in claim 126, and a pharmaceutically acceptable carrier therefor..Iaddend.

.Iadd.128. An antipsychotic composition which comprises a compound as claimed in claim 126, in an amount sufficient to produce an antipsychotic effect, and a pharmaceutically acceptable carrier therefor..Iaddend.

.Iadd.129. A method of treating psychoses, which comprises administering to a mammal a psychoses-treating effective amount of a compound as claimed in claim 126..Iaddend.

.Iadd.130. An analgesic composition which comprises a compound as claimed in claim 126, in an amount sufficient to produce a pain-relieving effect, and a pharmaceutically acceptable carrier therefor..Iaddend.

.Iadd.131. A method of alleviating pain, which comprises administering to a mammal a pain-relieving effective amount of a compound as claimed in claim 126..Iaddend.

.Iadd.132. A compound of formula ##STR00183## wherein X is --O-- or --S--; p is 1 or 2; Y is hydrogen, lower alkyl, hydroxy, chorine, fluorine, bromine, iodine, lower alkoxy, trifluoromethyl, nitro, or amino, when p is 1; Y is lower alkoxy, hydroxy or halogen when p is 2 and X is --O--; n is 2, 3, 4 or 5; R is hydrogen, lower alkyl, lower alkoxy, hydroxyl, carboxyl, chlorine, fluorine, bromine, iodine, amino, lower mono or dialkylamino, nitro, lower alkyl thio, trifluoromethoxy, cyano, acylamino, trifluoromethyl, trifluoroacetyl, aminocarbonyl, dialkylaminocarbonyl, formyl, --C(.dbd.O)-alkyl, --C(.dbd.O)-O-alkyl, --C(.dbd.O)-aryl, --C(.dbd.O)-heteroaryl, --CH(OR.sub.7)-alkyl, --C(.dbd.W)-alkyl, --C(.dbd.W)-aryl, or --C(.dbd.W)-heteroaryl; wherein alkyl is lower alkyl; aryl is phenyl or ##STR00184## wherein R.sub.5 is hydrogen, lower alkyl, lower alkoxy, hydroxy, chlorine, fluorine, bromine, iodine, lower monoalkylamino, nitro, cyano, trifluoromethyl, or trifluoromethoxy; heteroaryl is ##STR00185## wherein Q.sub.3 is --O--, --S--, --NH--, or --CH.dbd.N--; W is CH.sub.2 or CHR.sub.8 or N--R.sub.9; R.sub.7 is hydrogen, lower alkyl, or acyl; R.sub.8 is lower alkyl; R.sub.9 is hydroxy, lower alkoxy, or --NHR.sub.10; and R.sub.10 is hydrogen, lower alkyl, C.sub.1-C.sub.3 acyl, aryl, --C(.dbd.O)-aryl or --C(.dbd.O)-heteroaryl; wherein aryl and heteroaryl are as defined above; and m is 1, 2, or 3; with the proviso that at least one R is selected from the group consisting of dialkylaminocarbonyl, formyl, --C(.dbd.W)-alkyl, --C(.dbd.W)-aryl, and --C(.dbd.W)-heteroaryl; all geometric, optical and stereoisomers thereof, or a pharmaceutically acceptable acid addition salt thereof..Iaddend.

.Iadd.133. The compound of claim 132, wherein the pharmaceutically acceptable addition salt is selected from the group consisting of salts of mineral acids, salts of monobasic carboxylic acids, salts of dibasic carboxylic acids, and salts of tribasic carboxylic acids..Iaddend.

.Iadd.134. The compound of claim 133, wherein said pharmaceutically acceptable addition salts are selected from the group consisting of salts of hydrochloric acid, sulfuric acid, nitric acid, acetic acid, propionic acid, maleic acid, furmaric acid, carboxysuccinic acid, and citric acid..Iaddend.

.Iadd.135. The compound of claim 132, wherein Y is in the 5 position..Iaddend.

.Iadd.136. The compound of claim 132, wherein Y is in the 6 position..Iaddend.

.Iadd.137. The compound of claim 132, wherein Y is selected from the group consisting of hydrogen, chlorine, bromine and fluorine..Iaddend.

.Iadd.138. The compound of claim 137, wherein Y is fluorine..Iaddend.

.Iadd.139. The compound of claim 138, wherein Y is in the 6 position..Iaddend.

.Iadd.140. The compound of claim 132, wherein p is 2, X is --O--, and Y is selected from the group consisting of lower alkoxy, hydroxy and halogen groups..Iaddend.

.Iadd.141. The compond of claim 140, wherein Y is a methoxy group..Iaddend.

.Iadd.142. The compound of claim 132, wherein one R group is selected from the group consisting of hydrogen, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 alkoxy, hydroxyl, --COCF.sub.3, C.sub.1-C.sub.6 alkanoyl, Cl, F, Br,I, C.sub.1-C.sub.3 alkylamino, ##STR00186## .Iaddend.

.Iadd.143. A pharmaceutical composition, which comprises a compound as claimed in claim 132, and a pharmaceutical acceptable carrier therefor..Iaddend.

.Iadd.144. An antipsychotic composition which comprises a compound as claimed in claim 132, in an amount sufficient to produce an antipsychotic effect, and a pharmaceutically acceptable carrier therefor..Iaddend.

.Iadd.145. A method of treating psychoses, which comprises administering to a mammal a psychoses-treating effective amount of a compound as claimed in claim 132..Iaddend.

.Iadd.146. An analgesic composition which comprises a compound as claimed in claim 132, in an amount sufficient to produce a pain-relieving effect, and a pharmaceutically acceptable carrier therefor..Iaddend.

.Iadd.147. A method of alleviating pain, which comprises administering to a mammal a pain-relieving effective amount of a compound as claimed in claim 132..Iaddend.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc